VAIL, CO USA (UroToday.com) - Objectives: Radical prostatectomy (RP), brachytherapy, cryosurgical ablation and intensity-modulated radiotherapy (IMRT) are accepted treatment options for localized prostate cancer.

The objectives of this study are to determine the overall survival (OS), disease specific survival (DSS) and biochemical no evidence of disease (BNED) of the patients who underwent these different treatment modalities.

24th cap updateMaterials and Methods: A total of 485 patients with localized prostate cancer treated with RP (n=235), brachytherapy (n=202), cryosurgical ablation (n=33), and IMRT (n=15) were identified from the database of a single urological practice. Analysis of variance (ANOVA) was used to compare means of patients. Chi-square test was used to compare percentage. Kaplan-Meier survival analysis was used to determine if the outcome parameters significantly differ according to the methods. P-values less than 0.05 indicate significant difference. All the statistical tests were performed using SPSS 20.0.

Results: The OS after RP, brachytherapy, cryosurgical ablation and IMRT were 97.9%, 89.1%, 93.9% and 93.3%, respectively. The DSS was 99.6%, 98.0% and 97.0%. respectively. No mortality from prostatic cause was reported from IMRT. The BNED was 90.6%, 88.1%, 78.8% and 93.3%, respectively.

Conclusion: The overall and disease specific survival were comparable among all treatment modalities. Although brachytherapy and IMRT showed an overall better BNED outcome, this advantage disappeared when the patients are analyzed in accordance to their respective risk stratification into low, moderate and high risk group.

Presented by Marlon P. Martinez and Jason L. Letran at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

University of Santo Tomas Hospital, Espana Blvd., Manila, Philippines 1008

 

 

Calendar
Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Journals
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor